During the last session, Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s traded shares were 0.55 million, with the beta value of the company hitting 0.97. At the end of the trading day, the stock’s price was $4.34, reflecting an intraday gain of 5.34% or $0.22. The 52-week high for the MREO share is $5.02, that puts it down -15.67 from that peak though still a striking 71.89% gain since the share price plummeted to a 52-week low of $1.22. The company’s market capitalization is $667.32M, and the average intraday trading volume over the past 10 days was 0.7 million shares, and the average trade volume was 891.43K shares over the past three months.
Mereo Biopharma Group Plc ADR (MREO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.20. MREO has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Mereo Biopharma Group Plc ADR (MREO) registered a 5.34% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 5.34% in intraday trading to $4.34, hitting a weekly high. The stock’s 5-day price performance is -1.36%, and it has moved by -1.14% in 30 days. Based on these gigs, the overall price performance for the year is 231.30%. The short interest in Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is 4.88 million shares and it means that shorts have 6.19 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.5, which implies an increase of 42.13% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $8 respectively. As a result, MREO is trading at a discount of -84.33% off the target high and 7.83% off the low.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
In the rating firms’ projections, revenue will increase 41.60% compared to the previous financial year.
Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 14.43M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 41.78%. While earnings are projected to return 15.00% in 2024.
MREO Dividends
Mereo Biopharma Group Plc ADR is due to release its next quarterly earnings on 2024-Aug-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Mereo Biopharma Group Plc ADR insiders own 1.02% of total outstanding shares while institutional holders control 65.49%, with the float percentage being 66.17%. RUBRIC CAPITAL MANAGEMENT LP is the largest shareholder of the company, while 86.0 institutions own stock in it. As of 2024-06-30, the company held over 15.31 million shares (or 2.1859% of all shares), a total value of $55.11 million in shares.
The next largest institutional holding, with 11.79 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 1.6838% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $42.45 million.
